This ‘HER-2 paradigm’ may also be relevant for other breast cancer patients in whom successful control of the disease outside of the CNS is achieved with adjuvant or palliative chemo- and radiotherapy (Lin and Winer, 2007). The gene discussed is ERBB2; the disease is breast carcinoma.